Beth Nash, MD, Chief Medical Officer

Dr. Beth Nash is Chief Medical Officer at Real Endpoints, where her team of pharmacists and biostatisticians has developed a range of platforms to assess the value of drugs. Their flagship product, RxScorecard, is an interactive online tool which compares drugs within a disease sub-population based on efficacy, safety, ease of use and economic issues. Dr. Nash’s team also provided the technology and data analysis for DrugAbacus, the cancer drug pricing tool developed by Memorial Sloan Kettering Cancer Center.  Dr. Nash has presented industry webinars across a range of areas including immuno-oncology and multiple myeloma.

Prior to joining Real Endpoints, Dr. Nash was a healthcare consultant specializing in health innovation, patient experience, shared decision-making, and collaborative online networks. She previously managed online content across a wide array of therapeutic areas for the health group at Consumer Reports and for the BMJ Publishing Group. She has also served as Chief Medical Officer for a health internet start-up, been a managed care medical director, and was on the Infectious Diseases staff at the Mount Auburn Hospital in Cambridge, MA, where she developed their AIDS program.

Dr. Nash holds a BS degree from Cornell University. She received her MD degree and completed her residency training in Internal Medicine at the Albert Einstein College of Medicine. She completed her fellowship in Infectious Diseases at the Brigham and Women’s Hospital, Dana Farber Cancer Institute, Beth Israel Hospital and Harvard Medical School.

Our Team

Jeffrey Berkowitz

CEO and Director

Mr. Berkowitz is one of the rare top executives whose career has spanned most key verticals in global healthcare -- with executive committee and....

read full biography >

Susan Raiola


Susan Raiola is the President of Real Endpoints. Ms. Raiola has over 10 years of experience in the pharmaceutical consulting...

read full biography >

Roger Longman

Founder and Chairman

Mr. Longman is recognized as an expert in biopharmaceutical strategy and reimbursement and often speaks at key...

read full biography >

Norman C. Selby

Founder and Vice Chairman

Norman C. Selby has spent 35 years in the healthcare world in a variety of consulting, managerial, investor and Board roles...

read full biography >

Jane F. Barlow, MD, MPH, MBA

EVP & Chief Clinical Officer

Jane Barlow is a clinical and strategic executive with over 25 years of healthcare leadership...

read full biography >

Beth Nash, MD

Chief Medical Officer

Dr. Beth Nash is Chief Medical Officer at Real Endpoints, where her team of pharmacists and biostatisticians has developed...

read full biography >

Jane Borne, RPh

VP, Pharmacy

Jane Borne, RPh, is responsible for ensuring the clinical credibility and evidence basis of all RE drug evaluation activities...

read full biography >

Dirk Soutendijk

Principal Consultant

Dirk Soutendijk is a highly thought of Market Access Consultant within the BioPharmeutical Industry.  He has successfully developed and implemented....

read full biography >

Amy Steinkellner, PharmD

Senior Consultant

Amy Steinkellner, PharmD, has worked with the Real Endpoint team since 2012. She serves as senior clinical advisor to the research...

read full biography >

Robert Galvin, MD

Dr. Robert Galvin is the Chief Executive Officer of Equity Healthcare (EH), which oversees the management of health care for firms...

read full biography >

Michael Sherman, MD

Dr. Michael Sherman serves as Chief Medical Officer and senior vice president for Harvard Pilgrim Health Care...

read full biography >

Dennis Purcell

Dennis is the Founder, Senior Advisor, and previous Senior Managing Partner of Aisling Capital LLC.,  a leading investment firm...

read full biography >

Linda Blackerby

Linda has been serving as the President of Pharma Intelligence at Informa since May 2015, overseeing an income statement...

read full biography >

Arthur Pappas (Observer)

Art has over 30 years of experience as a pharmaceutical industry executive and venture capital investor in...

read full biography >